Madrigal Pharmaceuticals Inc (OQ:MDGL)

Jun 06, 2024 08:00 am ET
Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced results from new analyses of the Phase 3 MAESTRO-NASH trial of Rezdiffra...
Jun 05, 2024 08:00 am ET
Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024, and will present at 8:40 A.M. ET. The presentation will be...
May 29, 2024 08:00 am ET
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced ten data presentations at the upcoming European Association for the Study of...
May 07, 2024 07:00 am ET
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today reports first-quarter 2024 financial results and provides corporate updates. Bill...
Apr 24, 2024 04:00 pm ET
Madrigal Statement on the Passing of Dr. Stephen Harrison
The Madrigal team is shocked and saddened to learn of the passing of Dr. Stephen Harrison. We offer our deepest condolences to Stephen’s family for their loss. Stephen was a colleague and friend to so many of us at Madrigal. He worked tirelessly...
Apr 23, 2024 08:00 am ET
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2024 financial results on Tuesday, May 7, 2024, prior to the open of the U.S. financial markets. Following the announcement, Madrigal’s...
Apr 16, 2024 04:05 pm ET
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to 7 new employees, in each case with a grant date...
Apr 09, 2024 08:00 am ET
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Rezdiffra (resmetirom) is now available in the U.S. Rezdiffra is...
Apr 03, 2024 04:05 pm ET
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to 30 new employees, in each case...
Mar 18, 2024 11:58 pm ET
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced the pricing of its underwritten public offering of 750,000 shares of its...
Mar 18, 2024 04:04 pm ET
Madrigal Pharmaceuticals Announces Proposed Public Offering
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that it has commenced an underwritten public offering of $500 million in...
Mar 14, 2024 04:15 pm ET
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated...
Mar 06, 2024 04:05 pm ET
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to (i) Mardi C. Dier, the Company’s...
Mar 05, 2024 08:00 am ET
Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the Company’s Marketing Authorization Application (MAA) for...
Feb 28, 2024 07:01 am ET
Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Mardi C. Dier has been appointed Chief Financial Officer. Ms. Dier...
Feb 28, 2024 07:00 am ET
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today provides a summary of corporate updates and reports fourth quarter and full year...
Feb 21, 2024 08:00 am ET
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to 46 new employees, in each case...
Feb 08, 2024 08:00 am ET
Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced the publication of the pivotal Phase 3 MAESTRO-NASH trial of resmetirom in...
Feb 06, 2024 04:05 pm ET
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to seven new employees, in each...
Feb 06, 2024 08:31 am ET
Thinking about trading options or stock in Palantir Technologies, Symbotic, Super Micro Computer, Madrigal Pharmaceuticals, or Futu Holdings?
NEW YORK, Feb. 6, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PLTR, SYM, SMCI, MDGL, and FUTU.
Jan 29, 2024 08:00 am ET
Madrigal Pharmaceuticals Announces Additions to Its Leadership Team
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced three new members of its leadership team: Mark Barrett joins Madrigal as...
Jan 22, 2024 08:00 am ET
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to 109 new employees, in each case...
Jan 04, 2024 08:00 am ET
Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual Conference
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced five health economics abstracts being presented at the NASH-TAG...
Jan 03, 2024 04:30 pm ET
Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today that the Company will present at the 42nd Annual J.P. Morgan Healthcare...
Dec 22, 2023 04:30 pm ET
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to thirty-two new employees with a...
Nov 27, 2023 04:30 pm ET
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to (i) Carole Huntsman, the...
Nov 21, 2023 08:00 am ET
Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Ronald Filippo has been appointed Chief Information Officer. Mr....
Nov 15, 2023 04:45 pm ET
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to 18 new employees with a grant...
Nov 10, 2023 08:00 am ET
Madrigal Pharmaceuticals Presents New Data from the Phase 3 MAESTRO-NASH Trial Demonstrating Broad Treatment Effects of Resmetirom on Noninvasive Measures of Liver Health
Data to be featured in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting®Analyses from comprehensive set of noninvasive tests used in MAESTRO-NASH provide new insights on strategies to identify...
Nov 10, 2023 07:30 am ET
Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Carole Huntsman has been appointed Chief Commercial Officer. Ms....
Nov 06, 2023 08:00 am ET
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today provides a summary of recent corporate accomplishments, previews new Phase 3 MAESTRO...
Nov 02, 2023 04:05 pm ET
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in fireside chats at three upcoming...
Oct 12, 2023 04:05 pm ET
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to seven new employees with a grant...
Sep 28, 2023 10:30 pm ET
Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced the pricing of its underwritten public offering of 1,248,098 shares of...
Sep 28, 2023 04:01 pm ET
Madrigal Pharmaceuticals Announces Proposed Public Offering
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that it has commenced an underwritten public offering of $500 million in...
Sep 14, 2023 04:30 pm ET
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that it made an inducement grant to Bill Sibold on September 11, 2023 in...
Sep 13, 2023 09:10 am ET
Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review...
Sep 11, 2023 07:00 am ET
Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Bill Sibold has succeeded Paul Friedman, M.D., as Chief Executive...
Aug 08, 2023 08:00 am ET
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today provides a summary of recent corporate accomplishments and reports second quarter...
Jul 17, 2023 08:00 am ET
Madrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced the completion of the rolling submission of its New Drug Application (NDA) to...
Jun 30, 2023 08:00 am ET
Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug...
Jun 22, 2023 03:30 am ET
Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress™
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today presents resmetirom Phase 3 MAESTRO-NASH data at the opening general session of the...
Jun 06, 2023 08:00 am ET
Madrigal Pharmaceuticals Supports International NASH Day on June 8
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced its support for the sixth International NASH Day, taking place on June 8,...
Jun 01, 2023 08:00 am ET
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in fireside chats at two upcoming...
May 11, 2023 08:00 am ET
Madrigal Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in a fireside chat at the The JMP...
May 09, 2023 08:00 am ET
Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today provides a summary of corporate updates and reports first quarter 2023 financial...
Apr 18, 2023 08:00 am ET
Madrigal Receives Breakthrough Therapy Designation from FDA for Resmetirom and Completes Enrollment of the Phase 3 MAESTRO-NASH Biopsy Trial
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that resmetirom has received Breakthrough Therapy designation from the...
Feb 23, 2023 08:00 am ET
Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today provides a summary of corporate updates and reports fourth quarter and full year...
Feb 08, 2023 08:00 am ET
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in three upcoming investor...
Jan 06, 2023 08:00 am ET
Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced additional results from the pivotal Phase 3 MAESTRO-NASH biopsy clinical...
Dec 21, 2022 04:15 pm ET
Madrigal Pharmaceuticals Announces $300+ Million in Financing Events to Advance Resmetirom Program
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that it has raised $259 million in gross equity (or $255 million in net proceeds) from equity securities issuances and an additional $50 million in liquidity commitments following the...
Dec 19, 2022 08:31 am ET
Thinking about trading options or stock in Madrigal Pharmaceuticals, Amazon, Moderna, Apple, or Baidu?
NEW YORK, Dec. 19, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MDGL, AMZN, MRNA, AAPL, and BIDU.
Dec 19, 2022 07:00 am ET
Madrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced positive topline results from the pivotal Phase 3 MAESTRO-NASH biopsy...
Dec 18, 2022 04:00 pm ET
Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NASH Study of Resmetirom on Monday, December 19th
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), plans to announce topline results from the Phase 3 MAESTRO-NASH study of resmetirom on...
Nov 03, 2022 08:00 am ET
Madrigal Pharmaceuticals Provides an Overview of Upcoming Resmetirom Data Presentations and Reports 2022 Third Quarter Financial Results
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today provides an overview of upcoming resmetirom Phase 3 data presentations and reports...
Sep 07, 2022 08:00 am ET
Madrigal Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in a fireside chat at the H.C....
Aug 31, 2022 08:00 am ET
Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced initiation of the “MAESTRO-NASH Outcomes” study of resmetirom (recruiting,...
Aug 04, 2022 08:00 am ET
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today provides a summary of recent corporate accomplishments and reports its second...
Jun 25, 2022 09:00 am ET
Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced data from multiple resmetirom abstracts presented at the European...
Jun 06, 2022 08:00 am ET
Madrigal Pharmaceuticals Supports International NASH Day on June 9
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), today announced its support for the fifth International NASH Day, taking place on June 9,...
Jun 02, 2022 08:00 am ET
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), announced today its management team will participate in three upcoming investor...
May 17, 2022 08:00 am ET
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), announced today its management team will participate in two upcoming investor...
May 09, 2022 06:30 am ET
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial Results
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), today announced acceptance of four abstracts for oral presentation at the European...
Apr 28, 2022 08:00 am ET
Madrigal Pharmaceuticals to Announce First Quarter 2022 Financial Results and Provide Clinical and Business Updates on May 9
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), will report its first quarter 2022 financial results on Monday, May 9, 2022 and provide...
Mar 09, 2022 04:30 pm ET
Madrigal Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), announced today its management team will participate in the 32nd Annual Oppenheimer...
Feb 24, 2022 08:00 am ET
Madrigal Pharmaceuticals Provides Business and Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), today provides a summary of corporate accomplishments and reports its fourth quarter and...
Jan 31, 2022 07:00 am ET
Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), today announced positive topline clinical data from the placebo-controlled, double-blind portion of its Phase 3 MAESTRO-NAFLD-1 (non-alcoholic fatty liver disease) safety study of resmetirom. The...
Jan 30, 2022 04:00 pm ET
Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom on Monday, January 31st
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, plans to announce topline results from the Phase 3 MAESTRO-NAFLD-1 study of resmetirom on Monday,...
Jan 10, 2022 08:00 am ET
Dominic F. Labriola Joins Madrigal Pharmaceuticals as Chief Data and Analytics Officer
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, announced today that Dr. Dominic F. Labriola has joined Madrigal as Senior Vice President and Chief Data...
Dec 30, 2021 08:00 am ET
Madrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today provides an update on MAESTRO-NAFLD-1, its 52-week Phase 3 multi-center, double-blind, randomized, placebo-controlled study of resmetirom in patients with non-alcoholic fatty liver disease,...
Nov 23, 2021 07:00 am ET
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohepatitis (NASH), announced...
Nov 12, 2021 08:00 am ET
Positive Resmetirom Data from Completed Open-Label Portion of Phase 3 MAESTRO-NAFLD-1 Clinical Study Presented at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® Digita
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), today announced the presentation of positive clinical data from the open-label portion of its ongoing MAESTRO-NAFLD-1 (non-alcoholic fatty liver disease) study of resmetirom at the AASLD The Liver...
Nov 04, 2021 06:50 am ET
Madrigal Pharmaceuticals Provides Corporate Update and Reports 2021 Third Quarter Financial Results
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today provides a summary of corporate accomplishments and reports its third quarter 2021 financial results. Paul Friedman, M.D., Chief Executive Officer of Madrigal, stated, “Throughout the...
Oct 04, 2021 06:50 am ET
Madrigal Pharmaceuticals Announces Support of Fatty Liver Foundation’s Screening Fund to Improve Diagnosis and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (N
Madrigal Pharmaceuticals (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, announces its support of the Fatty Liver Foundation, the leading patient advocacy organization focused on the...
Aug 05, 2021 06:50 am ET
Madrigal Pharmaceuticals Reports 2021 Second Quarter Financial Results and Provides Corporate Update
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reports today its second quarter 2021 financial results and provides a summary of corporate accomplishments. Paul Friedman, M.D., Chief Executive Officer of Madrigal, stated, “The Madrigal team has made...
Aug 02, 2021 06:50 am ET
Robert Waltermire Joins Madrigal Pharmaceuticals as Chief Pharmaceutical Development Officer
Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need, announced today that Dr. Robert Waltermire has joined Madrigal as Chief...
Jul 13, 2021 05:47 pm ET
Madrigal Pharmaceuticals Offers Patients Resmetirom in a Planned Open Label Active Treatment Extension of the Phase 3 MAESTRO-NAFLD-1 Clinical Study
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its first patient dosed in a planned 52-week open label active treatment extension study of MAESTRO-NAFLD-1, named MAESTRO-NAFLD-1-Open Label Extension (OLE) (NCT04951219)....
Jun 30, 2021 06:50 am ET
Madrigal Pharmaceuticals Completes Enrollment of the 52 Week Liver Biopsy Patient Population in the Phase 3 MAESTRO-NASH Study of Resmetirom
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today achievement of the planned target enrollment in the Phase 3 clinical trial, MAESTRO-NASH. Serial liver biopsy and safety data from patients enrolled in MAESTRO-NASH coupled with safety...
Jun 25, 2021 11:30 am ET
Madrigal Pharmaceuticals Announces Presentation of Positive Clinical Data of Resmetirom from Open-Label Portion of Ongoing Phase 3 Clinical Trial MAESTRO-NAFLD-1 at The International Liver Congress™ 2
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), today announced the presentation of positive clinical data from the open-label portion of its ongoing Phase 3 MAESTRO-NAFLD-1 study of resmetirom at the European Association for the Study of the Liver...
Jun 08, 2021 06:50 am ET
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences
Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL), a clinical- stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohepatitis (NASH), announced...
May 21, 2021 09:38 am ET
Madrigal Pharmaceuticals to Participate in UBS Global Healthcare Virtual Conference
Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohepatitis (NASH), announced...
May 18, 2021 09:00 am ET
Madrigal Pharmaceuticals to Present at RBC Capital Markets Virtual 2021 Global Healthcare Conference on Wednesday, May 19, 2021 at 8:00 a.m. ET
Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohepatitis (NASH), announced...
May 18, 2021 06:50 am ET
Alex Howarth Joins Madrigal Pharmaceuticals as Chief Financial Officer
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need, announced today that Alex Howarth has joined Madrigal...
May 06, 2021 06:50 am ET
Madrigal Pharmaceuticals Reports 2021 First Quarter Financial Results and Highlights
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its first quarter 2021 financial results and highlights. “We expect several important events for Madrigal to occur in 2021,” stated Paul Friedman, M.D., Chief Executive Officer of...
Feb 25, 2021 06:50 am ET
Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its fourth quarter and full year 2020 financial results and highlights. “We are pleased with the substantial progress the Company made in 2020, particularly in light of the significant...
Nov 13, 2020 06:50 am ET
Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting November 13, 2020, Including NASH Expert In
Dr. Stephen Harrison will present Resmetirom for the Treatment of NASH: Early Data from the Phase 3 MAESTRO Clinical Trials | The Liver Meeting Digital Experience™, AASLD Product Theater on Friday, November 13, 2020, at 4:30 PM ET.In the 100 mg open...
Nov 05, 2020 06:50 am ET
Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it completed enrollment in its MAESTRO NAFLD-1 clinical trial of resmetirom in patients with presumed NASH who are diagnosed using non-invasive assessments. The Company also...
Oct 01, 2020 08:00 am ET
Madrigal Pharmaceuticals Announces Three Abstracts Accepted by The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting in November 2020, including Posit
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), announced today that, based on data from studies with MGL-3196 (resmetirom), three posters and an oral presentation of these data will be presented at The Liver Meeting Digital Experience™, The American...
Sep 03, 2020 06:50 am ET
Madrigal Pharmaceuticals Exceeds Target Enrollment in Phase 3 MAESTRO NAFLD-1 Trial
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it has already exceeded the originally targeted enrollment of 700 patients in its MAESTRO NAFLD-1 clinical trial of resmetirom in patients with NASH and fibrosis that is diagnosed...
Aug 26, 2020 06:50 am ET
Madrigal Pharmaceuticals to Present Secondary Analyses of Data from Phase 2 NASH Study of Resmetirom and Symposium at the Digital International Liver Congress™ 2020
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that on Friday, August 28, 2020 at the Digital International Liver Congress™ 2020, European Association for the Study of the Liver (EASL), secondary analyses of data from its Phase 2 NASH...
Aug 06, 2020 06:50 am ET
Madrigal Pharmaceuticals Reports 2020 Second Quarter Financial Results and Highlights
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its second quarter 2020 financial results and highlights: “The Madrigal team and our CRO’s are focused on completing enrollment of both of our Phase 3 MAESTRO clinical trials as rapidly...
May 07, 2020 06:50 am ET
Madrigal Pharmaceuticals Reports 2020 First Quarter Financial Results and Highlights
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its first quarter 2020 financial results and highlights: “Madrigal continued to make progress toward our clinical development and business objectives during the first quarter of 2020,...
Apr 14, 2020 06:50 am ET
Madrigal MAESTRO Phase 3 NASH Trials Continue without Protocol Modifications; New Data Demonstrate that Reductions in Liver Fat Achieved by Resmetirom Predict NASH Resolution and Fibrosis Reduction
-- MAESTRO Phase 3 clinical studies proceed, with more flexible allowances in visits and study drug dispensing for enrolled and screened patients at impacted sites, intended to maintain patient safety and trial integrity during the COVID pandemic....
Feb 26, 2020 06:50 am ET
Madrigal Pharmaceuticals Reports 2019 Fourth Quarter and Full Year Financial Results and Highlights
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its fourth quarter and full year 2019 financial results and highlights: “Madrigal made significant progress during 2019 in executing our business strategy and advancing the development...
Dec 18, 2019 06:50 am ET
Madrigal Pharmaceuticals Announces First Patient Dosed in MAESTRO-NAFLD-1, a Second Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Resmetirom (MGL-3196) in Patients With N
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it has dosed the first patient in its second Phase 3 clinical trial, MAESTRO-NAFLD-1 with its first-in-class, once daily, oral thyroid hormone receptor-beta selective agonist,...
Dec 10, 2019 11:58 pm ET
Madrigal Pharmaceuticals Announces Pricing of Secondary Offering
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal” or the “Company”), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular,...
Dec 10, 2019 04:01 pm ET
Madrigal Pharmaceuticals Announces Secondary Offering of 1,200,000 Shares of Common Stock
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal” or the “Company”), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular,...
Nov 11, 2019 05:30 pm ET
Madrigal Pharmaceuticals Announces Publication in The Lancet of Positive Phase 2 Results for Resmetirom (MGL-3196) for the Treatment of Non-alcoholic Steatohepatitis (NASH)
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today the online publication in The Lancet of the resmetirom (MGL-3196) Phase 2 multi-center, randomized, double-blind, placebo-controlled clinical trial in patients with non-alcoholic...
Nov 06, 2019 06:50 am ET
Madrigal Pharmaceuticals Reports 2019 Third Quarter Financial Results and Highlights
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its third quarter 2019 financial results and highlights: “Madrigal continued to execute its clinical development strategy in non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty...
Aug 07, 2019 06:50 am ET
Madrigal Pharmaceuticals Reports 2019 Second Quarter Financial Results and Highlights
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its second quarter 2019 financial results and highlights: “Madrigal has continued to progress on several important fronts during the second quarter.  We have moved forward with our Phase...
Jul 11, 2019 06:50 am ET
Madrigal Pharmaceuticals Promotes Rebecca Taub, M.D., Chief Medical Officer and Executive Vice President of Research & Development, to Newly Created Position of President of Research & Development
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today the promotion of Rebecca Taub, M.D., to the newly created positon of President of Research & Development. Dr. Taub has served as Chief Medical Officer and Executive Vice President of...
Jul 02, 2019 06:50 am ET
Madrigal Pharmaceuticals Announces Appointment of Jim Daly to Board of Directors
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that Jim Daly has been appointed to the Company’s Board of Directors, as a Class I director, effective as of June 27, 2019.  “We are extremely pleased to have an executive with Jim’s...
Jun 04, 2019 06:50 am ET
Madrigal Pharmaceuticals to Present at Upcoming Investment Conferences
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that Paul Friedman, M.D., Chief Executive Officer of Madrigal, and Becky Taub, M.D., CMO and Executive VP, Research & Development of Madrigal will present at the following conferences in...
May 15, 2019 04:42 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Certain Officers and Directors of Madrigal Pharmaceuticals, Inc.
Levi & Korsinsky announces it has commenced an investigation of Madrigal Pharmaceuticals, Inc. (NASDAQCM: MDGL) concerning possible breaches of fiduciary duty. To obtain additional information, go to:...
May 08, 2019 06:50 am ET
Madrigal Pharmaceuticals Reports 2019 First Quarter Financial Results and Highlights
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its first quarter 2019 financial results and highlights: “Madrigal continued to make significant progress in the first quarter of 2019, initiating a Phase 3 study of MGL-3196...
Apr 08, 2019 06:50 am ET
Madrigal Pharmaceuticals to Present Additional Analyses of Data from The Phase 2 NASH Study with MGL-3196 (resmetirom) at The International Liver Congress™ 2019
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that on Thursday, April 11, 2019 at the International Liver Congress™ 2019, European Association for the Study of the Liver (EASL) in Vienna, further in depth analyses of the Phase 2...
Mar 28, 2019 06:50 am ET
Madrigal Pharmaceuticals Initiates Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosi
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it has initiated its Phase 3 trial in NASH with its once daily, oral thyroid hormone receptor beta selective agonist, MGL-3196 (resmetirom). This double-blind, placebo-controlled...
Feb 27, 2019 06:50 am ET
Madrigal Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its fourth quarter and full year 2018 financial results and highlights: “Madrigal made significant progress in 2018 in advancing the development of MGL-3196. We successfully completed...
Nov 28, 2018 08:40 am ET
Report: Exploring Fundamental Drivers Behind CASI Pharmaceuticals, Booking, Enstar Group, Madrigal Pharmaceuticals, Dermira, and Kaiser Aluminum — New Horizons, Emerging Trends, and Upcoming Developme
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of CASI Pharmaceuticals, Inc. (NASDAQ:CASI), Booking Holdings Inc....
Nov 12, 2018 11:30 am ET
Phase 2 Results for Madrigal’s MGL-3196 in Non-Alcoholic Steatohepatitis (NASH) Presented during Presidential Plenary Clinical Session of The Liver Meeting® 2018
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced the oral presentation of statistically significant results from a double-blind, placebo-controlled 36-week Phase 2 clinical trial in patients with biopsy-proven non-alcoholic...
Nov 06, 2018 06:50 am ET
Madrigal Pharmaceuticals Reports 2018 Third Quarter Financial Results and Highlights Upcoming Clinical Events
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its third quarter 2018 financial results and described upcoming clinical events: “Madrigal made important progress thus far in 2018 to advance the development of MGL-3196, through...
Oct 19, 2018 08:15 am ET
Research Report Identifies Brookfield Asset Management, Becton, Dickinson, IPG Photonics, ASML Holding N.V, American National Insurance, and Madrigal Pharmaceuticals with Renewed Outlook — Fundamental
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Brookfield Asset Management Inc (NYSE:BAM), Becton, Dickinson and Company...
Aug 07, 2018 06:50 am ET
Madrigal Pharmaceuticals Reports 2018 Second Quarter Financial Results and Reviews Key Clinical Achievements
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its second quarter 2018 financial results and described recent clinical and corporate accomplishments including: Positive Phase 2 Clinical Results - MGL-3196 demonstrated highly...
Jun 06, 2018 11:14 pm ET
Madrigal Pharmaceuticals Prices Public Offering of Common Stock
Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases, today...
Jun 05, 2018 04:10 pm ET
Madrigal Pharmaceuticals Announces Proposed Public Offering of Common Stock
Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases, today...
May 31, 2018 06:50 am ET
Madrigal’s MGL-3196 Achieves Liver Biopsy Endpoints in Patients with Non-alcoholic Steatohepatitis (NASH) at 36 Weeks in Phase 2 Clinical Trial
-- Conference call scheduled for 8:30 AM Eastern Time today -- CONSHOHOCKEN, Pa., May 31, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL) today announced positive top-line, 36-week results from a Phase 2 clinical trial in...
May 29, 2018 07:40 am ET
Report: Exploring Fundamental Drivers Behind Vivint Solar, Peapack-Gladstone Financial, Madrigal Pharmaceuticals, Univest Corporation of Pennsylvania, Amtech, and Lithia Motors — New Horizons, Emergin
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Vivint Solar, Inc. (NYSE:VSLR), Peapack-Gladstone Financial Corporation...
May 08, 2018 06:50 am ET
Madrigal Pharmaceuticals Reports 2018 First Quarter Financial Results and Reviews Key Clinical Achievements
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its first quarter 2018 financial results.  During the first quarter, the Company also: Reported that MGL-3196 demonstrated highly statistically significant results for the primary...
Apr 04, 2018 08:20 am ET
Recent Analysis Shows Multi-Color, Madrigal Pharmaceuticals, SPX, AngioDynamics, Atara Biotherapeutics, and Quanex Building Products Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, April 04, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Multi-Color Corporation (NASDAQ:LABL), Madrigal Pharmaceuticals, Inc....
Mar 13, 2018 06:50 am ET
Madrigal Pharmaceuticals Reports 2017 Fourth Quarter and Year-End Financial Results, Reviews Key Corporate Achievements and Provides Clinical Update on MGL-3196
- MGL-3196 is a first-in-class, oral, once-daily, liver-directed, thyroid hormone receptor (THR) β -selective agonist that is being developed for patients with non-alcoholic steatohepatitis (NASH) and heterozygous familial hypercholesterolemia (HeFH) -
Feb 08, 2018 06:50 am ET
Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Heterozygous Familial Hypercholesterolemia (HeFH)
-- Statistically significant improvement achieved in the reduction of LDL cholesterol (LDL-C) with MGL-3196 compared to placebo, the primary endpoint of this 12-week Phase 2 clinical trial in HeFH patients on maximal statin therapy --
Feb 05, 2018 07:35 am ET
Consolidated Research: 2018 Summary Expectations for Kimball Electronics, Madrigal Pharmaceuticals, American Railcar Industries, H&R Block, Biogen, and Equinix — Fundamental Analysis, Key Performance
NEW YORK, Feb. 05, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Kimball Electronics, Inc. (NASDAQ:KE), Madrigal Pharmaceuticals,...
Jan 30, 2018 07:00 am ET
Madrigal Announces Acceptance of MGL-3196 Abstract for a Main Plenary Presentation at The International Liver Congress™ 2018
CONSHOHOCKEN, Pa., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL) today announced that Week 12 Phase 2 results for MGL-3196, its first-in-class, oral, once-daily, liver-directed, thyroid hormone receptor (THR) β-selective agonist, will be presented during a...
Dec 18, 2017 11:26 pm ET
Madrigal Pharmaceuticals Prices Public Offering of Common Stock
CONSHOHOCKEN, Pa., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for cardiovascular, metabolic and liver diseases, today announced the pricing of an underwritten...
Dec 18, 2017 06:50 am ET
Madrigal Pharmaceuticals Announces Proposed Public Offering of Common Stock
CONSHOHOCKEN, Pa., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for cardiovascular, metabolic and liver diseases, today announced that it has commenced an...
Dec 06, 2017 06:55 am ET
Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Biopsy-proven Non-alcoholic Steatohepatitis (NASH) in Phase 2 Clinical Trial
-- Statistically significant improvement in the relative decrease in liver fat in patients treated with MGL-3196 compared with placebo, determined by magnetic resonance imaging-estimated proton density fat fraction (MRI-PDFF) at 12-weeks, the primary end point in this Phase 2 proof-of-concept...
Nov 09, 2017 07:50 am ET
Madrigal Pharmaceuticals Reports 2017 Third Quarter Financial Results
- Top-line results from MGL-3196 Phase 2 clinical trials in NASH and HeFH expected in late 2017 and early 2018, respectively -
May 11, 2017 05:00 pm ET
Madrigal Pharmaceuticals Reports 2017 First Quarter Financial Results
 - Phase 2 clinical studies of MGL-3196, a liver-directed thyroid hormone receptor (THR) beta selective agonist, are underway in patients with non-alcoholic steatohepatitis (NASH) and familial hypercholesterolemia (HeFH) ­...
Feb 23, 2017 08:15 am ET
Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia (HeFH)
-- HeFH is the most common dominantly inherited disease, present in up to 1 in 200 people, in which there is a life-long burden of high LDL cholesterol build up requiring aggressive lipid lowering treatment --...
Nov 14, 2016 04:30 pm ET
Madrigal Reports Third Quarter 2016 Financial Results
- Successfully Completed Merger and Transition to Public Company -...
Oct 20, 2016 07:30 am ET
Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL-3196 in Patients with Non-alcoholic Steatohepatitis (NASH)
-- Study expected to provide proof-of-concept data in NASH for the first liver-directed, thyroid hormone receptor (THR) ß-selective agonist –...
Sep 19, 2016 07:30 am ET
Aug 11, 2016 07:30 am ET
Richard S. Levy, M. D., Appointed to Madrigal Board of Directors
FORT WASHINGTON, Pa., Aug. 11, 2016 (GLOBE NEWSWIRE) -- MADRIGAL PHARMACEUTICALS, Inc. (Nasdaq:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for cardiovascular, metabolic and liver diseases, today announced the appointment of Richard S. Levy, M. D., to its board of directors, effective immediately....
Jul 22, 2016 11:30 am ET
Madrigal Pharmaceuticals Completes Merger with Synta to Create Leading Cardiovascular-Metabolic Diseases and NASH Company
FORT WASHINGTON, Pa., July 22, 2016 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic and liver diseases, today announced the completion of its merger with Synta Pharmaceuticals Corp. (NASDAQ:SNTA) (through July 22, 2016), effective as of July 22, 2016....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.